{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:43:57Z","timestamp":1782787437932,"version":"3.54.5"},"reference-count":13,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtct.2026.03.017","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T16:22:02Z","timestamp":1774714922000},"page":"868-876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Pre-Transplant Hypomethylating Agents on Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome With Good or Intermediate-Risk Cytogenetics"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6350-3826","authenticated-orcid":false,"given":"Yanal","family":"Alnimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Qasrawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Soule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8399-2428","authenticated-orcid":false,"given":"Claire","family":"McAvoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5801-1760","authenticated-orcid":false,"given":"Natalie Jo","family":"Hawes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3569-8632","authenticated-orcid":false,"given":"Fevzi F.","family":"Yalniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.jtct.2026.03.017_bib0001","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","article-title":"Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized Phase III study of the EBMT (RICMAC Trial)","volume":"35","author":"Kr\u00f6ger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2026.03.017_bib0002","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s12185-014-1549-3","article-title":"Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes","volume":"99","author":"Kim","year":"2014","journal-title":"Int J Hematol"},{"issue":"5","key":"10.1016\/j.jtct.2026.03.017_bib0003","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2352-3026(24)00065-6","article-title":"Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial","volume":"11","author":"Stelljes","year":"2024","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.jtct.2026.03.017_bib0004","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.leukres.2014.09.008","article-title":"Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations","volume":"38","author":"Santini","year":"2014","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.jtct.2026.03.017_bib0005","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/ijc.33608","article-title":"Upfront transplantation may have better outcomes than pretransplant cytoreductive therapy for treating patients with MDS-EB-1 or MDS-EB-2","volume":"149","author":"Chen","year":"2021","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.017_bib0006","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.1002\/ajh.26013","article-title":"Influence of somatic mutations and pretransplant strategies in patients allografted for myelodysplastic syndrome or secondary acute myeloid leukemia","volume":"96","author":"Rautenberg","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.017_bib0007","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/bloodadvances.2020003654","article-title":"Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors","volume":"5","author":"Grunwald","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.017_bib0008","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/sim.3782","article-title":"Improving propensity score weighting using machine learning","volume":"29","author":"Lee","year":"2010","journal-title":"Stat Med"},{"issue":"11","key":"10.1016\/j.jtct.2026.03.017_bib0009","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.017_bib0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-025-01233-9","article-title":"Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a secondary analysis of an RCT","volume":"15","author":"Xue","year":"2025","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.jtct.2026.03.017_bib0011","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.bbmt.2014.05.010","article-title":"Upfront allogeneic stem cell transplantation after reduced-intensity\/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire","volume":"20","author":"Damaj","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"10.1016\/j.jtct.2026.03.017_bib0012","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood.V118.21.115.115","article-title":"A decision analysis of reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation for older patients with de-novo myelodysplastic syndrome (MDS): early transplantation offers survival benefit in higher-risk MDS","volume":"118","author":"Koreth","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2026.03.017_bib0013","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.2024025464","article-title":"Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes","volume":"145","author":"Garcia","year":"2025","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726002307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726002307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:56:39Z","timestamp":1782744999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726002307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666636726002307"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.03.017","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Pre-Transplant Hypomethylating Agents on Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome With Good or Intermediate-Risk Cytogenetics","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}